Abstract:Abstract Introduction PAC-C is a randomized, multicenter, phase III study comparing the efficacy and safety of PX-X vs the standard XP regimen as first-line therapy for advanced gastric cancer (AGC). Here we report the findings from a protocol-specified preliminary safety analysis. Methods Patients with previously untreated AGC, evaluable lesion(s) by RECIST 1.0, and KPS≥70 are eligible. All eligible patients are randomized to receive either PX-X or XP. Patients in the PX-X arm receive paclitaxel (80 mg/m2 3-hour infusion on days 1&8) and capecitabine (1000 mg/m2 twice daily on days 1–14) every 3 weeks for a maximum of 4 cycles; subsequently, patients with no disease progression receive maintenance capecitabine monotherapy (same dose/schedule) until progression or intolerable toxicity. Patients in the XP arm receive cisplatin (80 mg/m2 2-hour infusion on day 1) and capecitabine (same dose/schedule as in PX-X arm) for a maximum of 6 cycles. Adverse events (AEs) are evaluated according to CTC-AE (version 3.0). Study drug exposure, AEs and serious AEs (SAEs) were evaluated. The study is registered with ClinicalTrials.gov ID of NCT01015339. Results The study started in November 2009 and is anticipated to finish recruitment by the end of May 2012. Up to 30 June 2011, 160 patients were recruited (81 patients in the PX-X arm and 79 patients in the XP arm). The safety analysis population includes 147 patients (79 in the PX-X arm and 68 in the XP arm). Baseline patient and disease characteristics (median age, gender ratio, and performance status) were similar in the treatment arms. The median number of treatment cycles was 4.0 in each arm (range 1–22 cycles in the PX-X arm and 1–8 cycles in the XP arm). Dose adjustments of platinum or paclitaxel were lower in the PX-X arm (11.4% for paclitaxel) than the XP arm (30.9% for cisplatin); dose adjustments of capecitabine were also lower in the PX-X arm (6.3% vs 22.1% in the XP arm). AEs resulting in dose adjustment or administration delay were lower in the PX-X arm (10.1% vs 19.1%). Gastrointestinal AEs (all grades) were reported in 20.3% of PX-X and 32.4% of XP-treated patients. Grade 3/4 AEs in the PX-X vs XP arms were as follows: gastrointestinal (2.5% vs 5.9%); leukocytopenia (13.9% vs 13.2%); anemia (0% vs 7.4%). SAEs (6.3% vs 4.4%) and treatment-related deaths (1.2% vs 0%) were similar in the two treatment arms. Conclusion This preliminary analysis in 160 patients raises no safety concerns. The current findings suggest that treatment with PX-X is associated with fewer dose adjustments or treatment delays and a lower rate of gastrointestinal AEs than standard treatment with XP. The study is currently nearing completion of accrual.

Survival of Advanced Gastric Cancer Patients Treated with Maintenance Chemotherapy

Clinical observation of Capecitabine versus S-1 as maintenance therapy for advanced gastric cancer after the first-line inductive chemotherapy

144O Comparison of Efficacy and Safety of Paclitaxel and Capecitabine Followed by Capecitabine As Maintenance Therapy Versus Cisplatin and Capecitabine Therapy for Advanced Gastric Cancer: a Multicentre, Randomised, Active-Controlled Phase III Study

Capecitabine maintenance therapy after first-line chemotherapy in patients with metastatic colorectal cancer

Meta-Analysis Of Capecitabine-Based Chemotherapy Versus Capecitabine-Free Chemotherapy In Patients With Metastatic Breast Cancer

Clinical observation of capecitabine maintenance therapy after response to capecitabine -based combination chemotherapy in patients with metastatic breast cancer

Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer

A Phase Ii, Open-Label, Multicenter, Prospective Study of Paclitaxel Plus Capecitabine with Subsequent Capecitabine Maintenance Therapy As First-Line Treatment for Metastatic or Recurrent Gastric Cancer

Observation on Efficacy of Tegafur Gimeracil Oteracil Potassium Capsules Combined with Oxaliplatin in Treatment of Advanced Gastric CancerΔ

The Multicenter, Phase Ii Prospective Study of Paclitaxel Plus Capecitabine As First-Line Chemotherapy in Advanced Gastric Carcinoma

[Capecitabine Combined with Cisplatin As First-Line Therapy in Chinese Patients with Advanced Gastric Carcinoma-a Phase II Clinical Study].

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients.

A Retrospective Exploration of Targeted Maintenance Therapy in Advanced Colorectal Cancer: Based on the Background of Chinese Patient Assistance Program.

Capecitabine Maintenance Therapy for XT Chemotherapy-Sensitive Patients with Metastatic Triple-Negative Breast Cancer.

Capecitabine (X) Combined with Fractionated Cisplatin (C) As First-Line Therapy in Chinese Patients (pts) with Advanced Gastric Carcinoma (AGC)

Long-term Survival of an Elderly Female with Metastatic Colon Cancer after Treated with Capecitabine Monotherapy

Oxaliplatin combined with 5-fluorouracil and docetaxel respectively for first-line treatment of advanced gastric cancer curative effect analysis

Combination of Paclitaxel, Cisplatin, and Fluorouracil in Patients with Advanced and Metastatic Gastric Cancer As First- or Second-Line Therapy: A Multicenter Prospective Study.

Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity.

Clinical observation of paclitaxel liposome combined with capecitabine in the treatment of advanced gastric cancer

P-0042 Preliminary Safety Analysis From PAC-C Study of Capecitabine+Paclitaxel→Capecitabine Maintenance (PX-X) vs Capecitabine+Cisplatin (XP) As First-Line Chemotherapy for Recurrent/Metastatic Gastric Cancer